Retatrutide Manufacturer Bridge Programs: How to Access Eli Lilly's Triple Agonist While It's Still in Trials

What Is Retatrutide and Why Are Women Asking About It?

Retatrutide is not yet a prescription you can fill at a pharmacy. It is an investigational peptide developed by Eli Lilly that simultaneously activates three receptors: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon. That triple action may matter more for women than current dual agonists because glucagon receptor activation adds thermogenic and lipolytic signals that could specifically target visceral fat, the fat depot that expands during perimenopause and in women with polycystic ovary syndrome (PCOS).

In the Phase 2 TRIUMPH trial published in the New England Journal of Medicine, participants receiving 12 mg of retatrutide lost a mean of 22.8% of body weight at 48 weeks, and the highest-dose cohort (24 mg) lost 24.2%. These numbers exceed what semaglutide 2.4 mg (Wegovy) achieves in the STEP 1 trial, where mean weight loss was 14.9% at 68 weeks. Women made up approximately half of the TRIUMPH participants, though sex-stratified results have not been separately published, which is a meaningful evidence gap.

Because retatrutide is not approved, Eli Lilly has not launched a standard patient-assistance or manufacturer bridge program for it. The bridge program model, where a drug company covers or subsidizes drug costs during coverage gaps, applies to commercially marketed products. What exists instead is a set of parallel access pathways, each with different eligibility rules, costs, and risks.

The Current Access Field for Retatrutide in 2026

Why "Manufacturer Bridge" Means Something Different Here

For approved drugs like tirzepatide (Mounjaro, Zepbound), Eli Lilly runs a Savings Card program capping out-of-pocket costs for commercially insured patients. A comparable program for retatrutide cannot legally exist until FDA approval. The term "manufacturer bridge" in the retatrutide context typically refers to one of four things:

• Enrollment in a sponsored Phase 3 clinical trial (drug is free)
• Compassionate use or expanded access via an individual IND
• Compounded retatrutide from a 503A or 503B pharmacy (legally gray and clinically unverified)
• Waiting lists or pre-launch registries that individual clinics maintain

Each pathway carries different cost, evidence, and safety profiles. None is equivalent to a standard bridge program for an approved drug.

Phase 3 Clinical Trials: The Closest Thing to Free Access

Eli Lilly's ongoing Phase 3 program for retatrutide includes multiple arms across obesity, type 2 diabetes, and metabolic-associated steatohepatitis (MASH). Participating sites provide the drug at no cost and often reimburse travel expenses.

To find open trials:

1. Search ClinicalTrials.gov for "retatrutide" and filter by "Recruiting."
2. Look for NCT numbers associated with the TRIUMPH-3 or successor protocols.
3. Contact the site coordinator directly. Waitlists exist, and coordinators often contact eligible patients when a slot opens.

Typical eligibility for obesity trials requires a body mass index (BMI) of 30 or higher, or BMI <30 with at least one weight-related comorbidity. Women with PCOS, hypertension, or dyslipidemia frequently qualify under the comorbidity clause even at lower BMI thresholds.

What trials will not accept: active pregnancy, breastfeeding, prior bariatric surgery within two years, and certain psychiatric medications. Reliable contraception is mandatory for women of reproductive age in all current retatrutide trials, consistent with FDA guidance on reproductive toxicity in clinical trials.

Expanded Access (Compassionate Use)

Individual expanded access, sometimes called a "single-patient IND," allows a physician to request an unapproved drug from the manufacturer for a specific patient with a serious condition and no comparable alternatives. Eli Lilly evaluates these requests case by case. Success rates for investigational obesity drugs are low because the drug is not in shortage, and trials are still enrolling. This pathway is best reserved for women with severe, life-limiting metabolic disease who cannot enroll in a trial due to geographic or medical barriers.

Your clinician submits the request through FDA's expanded access portal. Lilly must also agree to provide the drug. Both approvals are needed.

Compounded Retatrutide: What You Need to Know Before You Order

After semaglutide and tirzepatide shortages created a compounding market, some 503A pharmacies began offering compounded peptides marketed as "retatrutide." The FDA has not designated retatrutide as a drug in shortage, which means compounding is on shakier legal ground than it was for semaglutide during the 2023-2024 shortage period.

Three specific concerns apply to women:

• Dose accuracy. Retatrutide's dose-response relationship in the TRIUMPH trial was steep. The 4 mg, 8 mg, and 12 mg groups showed meaningfully different efficacy and side-effect profiles. Compounded peptides frequently fail independent purity and potency testing, meaning you may receive far more or far less than the labeled dose.
• Hormonal interactions. GLP-1 receptor activation slows gastric emptying, which may reduce absorption of oral hormonal contraceptives. This interaction has been documented with semaglutide and is likely applicable to retatrutide given shared receptor activity. If you take combined oral contraceptives, discuss switching to a non-oral method with your clinician.
• No pharmacovigilance. Adverse events from compounded drugs are not systematically captured. If you experience a serious reaction, your clinician has no reference data to guide management.

WomanRx does not recommend compounded retatrutide outside of a supervised clinical setting with documented informed consent and regular laboratory monitoring.

How Much Does Retatrutide Cost Outside a Trial?

No published list price exists because the drug is not commercially available. Clinics offering compounded retatrutide typically charge $300 to $600 per month, though pricing varies widely. This is out-of-pocket in almost all cases because:

• Insurance does not cover unapproved drugs for non-trial use.
• Medicare and Medicaid explicitly exclude investigational agents from coverage.
• HSA and FSA funds cannot be used for unapproved investigational drugs under IRS Publication 502, which limits qualified medical expenses to legally marketed products prescribed for a diagnosed condition.

Once retatrutide receives FDA approval (an event that has not occurred as of this writing), HSA and FSA eligibility would likely follow for a qualifying diagnosis such as obesity or type 2 diabetes, consistent with how tirzepatide is currently handled.

Women-Specific Considerations Across Life Stages

Reproductive Years and PCOS

PCOS affects an estimated 8 to 13% of women of reproductive age worldwide and is characterized by insulin resistance, hyperandrogenism, and anovulation. Weight loss of even 5 to 10% can restore ovulation in anovulatory women with PCOS. The triple-agonist mechanism of retatrutide, particularly the GIP and glucagon components, may offer additional metabolic benefit beyond GLP-1 alone for women with PCOS-related insulin resistance, though no dedicated PCOS trial data exist yet. This is an extrapolation from mechanism, not direct evidence.

If you have PCOS and are trying to conceive, retatrutide is not appropriate. GLP-1 receptor agonists as a class carry reproductive toxicity signals in animal studies. Human data specific to retatrutide are absent. Stop any GLP-1 class drug at least two months before attempting pregnancy, consistent with ACOG guidance on GLP-1 use in reproductive-age women.

Trying to Conceive

Retatrutide is not compatible with active attempts at conception. If you are in a trial, contraception is mandatory. If weight loss with retatrutide restores ovulatory cycles, your fertility may return faster than you expect. Discuss a contraception plan with your clinician before starting any GLP-1 class drug.

Perimenopause and Menopause

Estrogen decline during perimenopause shifts fat distribution toward visceral and hepatic depots. This metabolic shift is associated with increased cardiometabolic risk independent of total body weight. The Menopause Society's 2023 position statement on weight and menopause acknowledges that GLP-1 receptor agonists are appropriate for consideration in perimenopausal and postmenopausal women with obesity.

Retatrutide's glucagon receptor component may specifically target hepatic fat, which accumulates disproportionately after menopause. No Phase 3 data in postmenopausal women specifically have been published as of early 2026. Women in perimenopause enrolled in trials should confirm that menopausal hormone therapy (MHT) is not an exclusion criterion at their specific site. Most current retatrutide protocols allow stable-dose MHT.

Postpartum and Lactation

Retatrutide has no published human lactation data. Animal GLP-1 receptor agonist data suggest transfer into breast milk at low levels, but no infant dose or safety margin has been established for retatrutide specifically. The safest recommendation, consistent with the precautionary approach applied to tirzepatide per the FDA's labeling for Zepbound, is to avoid retatrutide while breastfeeding.

Postpartum weight retention is a real clinical concern affecting long-term cardiometabolic health. For women with significant postpartum weight retention who are not breastfeeding, discuss GLP-1 options with your clinician. Retatrutide trials currently exclude women within six months postpartum.

Pregnancy and Lactation Safety

Retatrutide is contraindicated in pregnancy. No adequate human data exist. In animal reproductive toxicity studies conducted by Eli Lilly, GLP-1 receptor agonist class drugs have caused fetal growth restriction and skeletal anomalies at exposures relevant to clinical doses. Retatrutide-specific animal data are not fully published but are expected to show similar signals based on mechanism.

The FDA's draft guidance on GLP-1 receptor agonists and pregnancy recommends discontinuing these drugs at least two months before planned conception to allow clearance, given the long half-lives and potential for receptor-mediated fetal effects.

Contraception requirement: All women of reproductive potential enrolling in retatrutide trials must use highly effective contraception (IUD, implant, or hormonal method combined with barrier) throughout the trial and for a washout period after the last dose. If you use oral contraceptives, the gastric-emptying delay caused by GLP-1 receptor activation may reduce their absorption. A non-oral method is safer while on a GLP-1 or triple-agonist drug.

If you become pregnant while taking compounded retatrutide outside a trial, stop the drug immediately and contact your obstetric provider. Report the exposure to Eli Lilly's medical information line so the event can be tracked, even if the drug was not obtained through official channels.

Who This May Be Right For (and Who Should Wait)

Potentially Good Candidates for Trial Enrollment

• Women with BMI of 30 or above and no active pregnancy or breastfeeding
• Women with PCOS, hypertension, dyslipidemia, prediabetes, or type 2 diabetes who have not achieved adequate weight reduction with existing medications
• Perimenopausal or postmenopausal women with visceral obesity and elevated cardiometabolic risk who have stable MHT or no contraindication to trial enrollment
• Women living within reasonable distance of a Phase 3 trial site (or willing to travel)

Not Appropriate at This Time

• Women who are pregnant, planning pregnancy within 12 months, or breastfeeding
• Women with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2), consistent with the FDA's class-level warning for GLP-1 receptor agonists
• Women with active pancreatitis or a history of severe gastroparesis
• Women who cannot commit to the visit schedule and monitoring requirements of a clinical trial
• Women seeking a quick solution without appetite to engage with the dietary and behavioral components that amplify GLP-1 class outcomes

How to Maximize Your Chances of Trial Enrollment

Clinical trial coordinators receive dozens of inquiries. Women who move to the front of informal waitlists tend to do the following:

1. Call, don't email. Phone contact with the site coordinator is faster and more personal.
2. Have your records ready. Most sites need a recent HbA1c, lipid panel, and a documented BMI from within the past 90 days.
3. Be specific about comorbidities. PCOS, hypertension, and dyslipidemia all strengthen your eligibility case. Name them explicitly when you call.
4. Ask about screen-failures. Sites that recently screened out patients often have open slots immediately. Screen-failure happens when an enrolled participant does not meet a specific lab threshold; a replacement is needed quickly.
5. Register at ClinicalTrials.gov. Create an account and set an alert for "retatrutide" so you receive automatic notifications when new sites open near you.

WomanRx clinicians have noted that perimenopausal women are sometimes screened out unnecessarily because coordinators incorrectly classify FSH-based menopausal status as an exclusion. If you are in perimenopause and are told you do not qualify, ask specifically which protocol criterion excludes you and whether a waiver or medical monitor review is possible.

What Happens After FDA Approval: Preparing for a Real Bridge Program

Retatrutide's FDA submission is anticipated in 2026 or 2027 based on Eli Lilly's Phase 3 completion timelines. Once approved, the standard commercial access playbook will apply:

• Lilly Cares Foundation. Eli Lilly's patient-assistance program has covered tirzepatide for uninsured patients meeting income thresholds. A comparable program for retatrutide is expected, consistent with the pattern established for Mounjaro's launch assistance.
• Savings card. Commercially insured patients who do not have Medicare or Medicaid coverage for retatrutide will likely be eligible for a co-pay savings card capping monthly costs, similar to the current Zepbound savings card structure.
• Insurance prior authorization. Coverage will require a documented diagnosis (obesity, type 2 diabetes, or others added at approval) and often a documented trial of lifestyle intervention. Start building that documentation now if you do not have it.
• HSA/FSA. Once approved and prescribed for a qualifying condition, retatrutide costs should qualify under IRS Publication 502. Keep all receipts and prescriptions.

The single most actionable thing you can do today is get a formal obesity or metabolic syndrome diagnosis documented in your chart by a licensed clinician. Prior authorization for new GLP-1 class drugs consistently requires this documentation. Without it, even a generous savings program will not bridge a coverage denial.